The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
A Spanish study finds that even if a sustained viral response is not achieved with combination therapy, those who had a partial response to Hepatitis C treatment fared better than those with no response at all.
Continue reading »An international, Phase III study reports that 65 percent of previous non-responders with the most common Hepatitis C genotype achieved a sustained viral response with a telaprevir-based regimen. These results are dramatic, compared to the mere 17 percent of sustained viral response by those who received pegylated-interferon and ribavirin alone.
Continue reading »Researchers from England have been able to transform skin cells into liver cells - a feat that could have major implications for those fighting Hepatitis C.
Continue reading »A recent television news piece helped boost awareness of Hepatitis C - but it also may have created false hope by alluding to the speedy arrival of a Hep C cure.
Continue reading »INX-189, Inhibitex's nucleotide polymerase inhibitor in development to fight chronic Hepatitis C, passes the first stage of human testing by demonstrating its safety.
Continue reading »Learn the facts about how acupuncture can help chronic Hepatitis C - and what feats are beyond its reach.
Continue reading »New evidence implies that milk thistle interrupts the Hepatitis C virus' reproduction and proliferation cycles.
Continue reading »Combining antiviral activity with a barrier to resistance, Pharmasset Inc.'s Hepatitis C drug, PSI-7977, has received fast track status by the FDA.
Continue reading »In general, the children of women infected with Hepatitis C have a low risk of being born with the virus. In addition to what was previously known about this type of Hepatitis C transmission, new research finds a genetic link that can aid - or prevent - this from occurring.
Continue reading »Due to recently released Phase III trial results, telaprevir has a better chance of gaining FDA approval by 2011. Researchers found that adding telaprevir to pegylated interferon and ribavirin takes half the time to achieve superior results than does standard Hepatitis C therapy.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
